Oncolytics Biotech Stock Performance
| ONCY Stock | USD 0.63 0.01 1.61% |
The company holds a Beta of 0.64, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Oncolytics Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Oncolytics Biotech is expected to be smaller as well. At this point, Oncolytics Biotech has a negative expected return of -0.53%. Please make sure to check Oncolytics Biotech's maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Oncolytics Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Oncolytics Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 34.9 M |
Oncolytics |
Oncolytics Biotech Relative Risk vs. Return Landscape
If you would invest 91.00 in Oncolytics Biotech on December 23, 2024 and sell it today you would lose (28.00) from holding Oncolytics Biotech or give up 30.77% of portfolio value over 90 days. Oncolytics Biotech is currently does not generate positive expected returns and assumes 3.8885% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Oncolytics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oncolytics Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncolytics Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncolytics Biotech, and traders can use it to determine the average amount a Oncolytics Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1356
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ONCY |
Estimated Market Risk
| 3.89 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.53 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Oncolytics Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncolytics Biotech by adding Oncolytics Biotech to a well-diversified portfolio.
Oncolytics Biotech Fundamentals Growth
Oncolytics Stock prices reflect investors' perceptions of the future prospects and financial health of Oncolytics Biotech, and Oncolytics Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncolytics Stock performance.
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.74 | ||||
| Current Valuation | 43.92 M | ||||
| Shares Outstanding | 86.42 M | ||||
| Price To Earning | (2.06) X | ||||
| Price To Book | 12.94 X | ||||
| EBITDA | (34.88 M) | ||||
| Cash And Equivalents | 32.36 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 1.06 M | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (26.97 M) | ||||
| Earnings Per Share | (0.29) X | ||||
| Total Asset | 20.19 M | ||||
| Retained Earnings | (477.71 M) | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 2.91 M | ||||
About Oncolytics Biotech Performance
Evaluating Oncolytics Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Oncolytics Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncolytics Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Oncolytics Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.Things to note about Oncolytics Biotech performance evaluation
Checking the ongoing alerts about Oncolytics Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncolytics Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncolytics Biotech generated a negative expected return over the last 90 days | |
| Oncolytics Biotech has some characteristics of a very speculative penny stock | |
| Oncolytics Biotech has high historical volatility and very poor performance | |
| Oncolytics Biotech has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (31.71 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech currently holds about 32.36 M in cash with (26.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. |
- Analyzing Oncolytics Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncolytics Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Oncolytics Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncolytics Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncolytics Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncolytics Biotech's stock. These opinions can provide insight into Oncolytics Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.